Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
AMC Networks Inc. (NASDAQ: AMCX) shares increased 3.21 percent to close at $63.29 a share Thursday. The stock traded between $61.64 and $64.04 on volume of 731,976 shares traded. B Riley has upgraded the company’s rating to "buy" from "neutral" and has also raised its price target to $76.00. Shares of AMC Networks have gained approximately 28.0 percent year-to-date.
Get more information on AMC Networks and free access to the in-depth equity report at:
Campbell Soup Company (NYSE: CPB) shares declined 3.09 percent to close at $43.33 a share Thursday. The stock traded between $42.87 and $43.72 on volume of 3.09 million shares traded. The company reported a net loss of $158 million for the fiscal fourth quarter, compared with net earnings of $127 million a year ago. Shares of Campbell Soup Company have gained approximately 25.0 percent year-to-date.
Get more information on Campbell Soup Company and free access to the in-depth equity report at:
Methode Electronics Inc. (NYSE: MEI) shares soared 32.50 percent to close at $23.36 a share Thursday. The stock traded between $22.40 and $25.00 on volume of 2.03 million shares traded. The company reported net sales were $167.3 million for the first quarter of fiscal 2014, an increase of 40.9 percent when compared to a year ago. Shares of Methode Electronics have gained approximately 130.0 percent year-to-date.
Get more information on Methode Electronics and free access to the in-depth equity report at:
Pharmacyclics, Inc. (NASDAQ: PCYC) shares increased 2.72 percent to close at $114.74 a share Thursday. The stock traded between $113.56 and $118.46 on volume of 891,617 shares traded. The company announced that its new drug application for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been accepted by the FDA. Shares of Pharmacyclics have gained approximately 98.0 percent year-to-date.
Get more information on Pharmacyclics and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...